Medpace stock heads into October 21 results after a 2.84 percent fall

Published on 10/07/2026 at 00:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medpace stock was last at USD 602.90 on October 6, 2026, down 2.84 percent. Q2 revenue rose 17.2 percent to USD 707.3 million before October 21 results.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Medpace Holdings stock (ISIN US58506Q1094) was last at USD 602.90 on Nasdaq on October 6, 2026, down 2.84 percent from the prior close. The next scheduled company event is the third-quarter 2026 results release on October 21, 2026, after the market close, according to Business Wire.

October 21 results set the next test

The upcoming release follows a second quarter that combined double-digit growth with an earnings beat. For investors, the central question is whether that operating pace can carry into the second half of 2026.

Business Wire reported that Medpace revenue for the quarter ended June 30, 2026, rose 17.2 percent year over year to USD 707.3 million. The company also reported diluted EPS of USD 4.25, compared with a consensus estimate of USD 3.98, a USD 0.27 beat.

Revenue growth beat consensus

The second-quarter revenue result exceeded the USD 689.51 million analyst estimate cited by MarketBeat. That USD 17.82 million difference, alongside the 17.2 percent year-over-year increase, gives the October report a clear operating benchmark.

Medpace is a clinical research organization serving biotechnology, pharmaceutical and medical-device companies across drug development stages, according to its investor-relations site. The business model links revenue to customer trial activity, making new awards, backlog and delivery execution important details for the next update.

Analysts hold at USD 602.27

The analyst consensus remains Hold, with three Buy ratings and ten Hold ratings and an average target of USD 602.27, according to MarketBeat. The average target is USD 0.63 below the October 6 last price, putting valuation alongside execution as the key measure for the coming results.

MarketBeat also reported that Chief Executive August Troendle sold 2,410 shares on September 28, 2026, at an average price of USD 620.07. That filing adds an insider-transaction counterpoint to the strong quarterly growth figures.

MEDP stays below its yearly high

Medpace was last at USD 602.90 on Nasdaq on October 6, 2026, with a 52-week range of USD 373.00 to USD 677.90 and a market capitalization of USD 16.8 billion. The stock remains USD 75.00 below its yearly high, while the scheduled October 21 report supplies the next dated operating checkpoint.